Business
Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the European Lung Cancer Congress 2025
SYDNEY, AUSTRALIA, March 20, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces an upcoming poster presentation for the pivotal TACTI-004 Phase III trial. The poster will be presented at the European Lung Cancer Congress (ELCC) 2025, taking place in Paris, France, from 26-29 March 2025. The Trial in Progress poster includes an overview and study design of the
About this update from Immutep Ltd
[{"type":"image","alt":"Immutep Limited","displaySize":"","headline":null,"caption":"Immutep Limited","className":"","disableSlideshowImg":false,"size":{"original":{"width":246,"height":103,"url":"https://media.zenfs.com/en/globenewswire.com/60325dae98d9e851c4236017024da578"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/PIIfOSI4irhaeByOTtn6bg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE3NjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/60325dae98d9e851c4236017024da578","width":246,"height":103}},"lazy":false},{"type":"text","content":"SYDNEY, AUSTRALIA, March 20, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces an upcoming poster presentation for the pivotal TACTI-004 Phase III trial. The poster will be presented at the European Lung Cancer Congress (ELCC) 2025, taking place in Paris, France, from 26-29 March 2025.","length":431,"tagName":"p"},{"type":"text","content":"The Trial in Progress poster includes an overview and study design of the TACTI-004 Phase III evaluating the Company’s MHC Class II agonist, eftilagimod alfa (efti) in combination with MSD’s (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 KEYTRUDA® (pembrolizumab) and chemotherapy as first line therapy for patients with advanced or metastatic non-small cell lung cancer (1L NSCLC). The global trial will enrol approximately 750 patients regardless of PD-L1 expression and with non-squamous or squamous tumours at over 150 clinical sites in over 25 countries.","length":563,"tagName":"p"},{"type":"text","content":"Immutep CSO, Frédéric Triebel, M.D., Ph.D, said, “We look forward to engaging with physicians in the lung cancer community at the ELCC conference to discuss our TACTI-004 Phase III study that is actively recruiting patients. Efti in combination with KEYTRUDA may change the treatment paradigm for patients with advanced or metastatic non-small cell lung cancer, irrespective of their PD-L1 expression, and we hope to see this registrational trial confirm the promising safety and efficacy achieved to date.”","length":507,"tagName":"p"},{"type":"text","content":"Details for the poster presentation:Title: TACTI-004: a double-blinded, randomized phase 3 trial in patients with advanced/metastatic non-small cell cancer receiving eftilagimod a...